WOLVERINE TRADING, LLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 443 filers reported holding CRISPR THERAPEUTICS AG in Q4 2021. The put-call ratio across all filers is 1.13 and the average weighting 0.2%.

Quarter-by-quarter ownership
WOLVERINE TRADING, LLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$5,776,331
-13.8%
127,260
+8.3%
0.01%
-25.0%
Q2 2023$6,699,907
+191819.4%
117,501
+48.7%
0.01%
+33.3%
Q1 2023$3,491
-8.2%
79,041
-15.5%
0.01%
+20.0%
Q4 2022$3,802
-99.9%
93,526
-5.0%
0.01%
-50.0%
Q3 2022$6,351,000
-16.3%
98,472
-18.3%
0.01%
-23.1%
Q2 2022$7,592,000
-16.1%
120,512
-14.7%
0.01%
+8.3%
Q1 2022$9,050,000
-42.9%
141,236
-29.8%
0.01%
-36.8%
Q4 2021$15,855,000
-23.5%
201,086
+6.9%
0.02%
-17.4%
Q3 2021$20,721,000
-40.8%
188,028
-19.2%
0.02%
-57.4%
Q2 2021$35,020,000
+26.3%
232,702
-3.3%
0.05%
+25.6%
Q1 2021$27,735,000
+9.5%
240,751
+53.6%
0.04%
+7.5%
Q4 2020$25,325,000
+302.5%
156,747
+111.7%
0.04%
+166.7%
Q3 2020$6,292,000
-4.1%
74,035
-15.3%
0.02%
-16.7%
Q2 2020$6,564,000
+122.0%
87,456
+31.0%
0.02%
+100.0%
Q1 2020$2,957,000
-15.2%
66,773
+18.5%
0.01%
+12.5%
Q4 2019$3,485,000
+36.6%
56,357
-6.4%
0.01%0.0%
Q3 2019$2,551,000
-33.7%
60,200
-26.3%
0.01%
-27.3%
Q2 2019$3,848,000
+67.5%
81,700
+27.1%
0.01%
+83.3%
Q1 2019$2,297,000
+44.1%
64,300
+7.9%
0.01%
+50.0%
Q4 2018$1,594,000
-40.0%
59,600
-0.5%
0.00%
-33.3%
Q3 2018$2,655,00059,8710.01%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q4 2021
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$31,294,00031.24%
NEA Management Company, LLC 1,590,002$365,593,00010.56%
Ariose Capital Management Ltd 37,900$2,379,0009.30%
ARK Investment Management 9,404,071$590,294,0002.46%
NIA IMPACT ADVISORS, LLC 80,082$5,027,0002.44%
Nikko Asset Management Americas, Inc. 4,619,747$291,044,0002.14%
PLUSTICK MANAGEMENT LLC 50,000$3,139,0001.98%
Integral Health Asset Management, LLC 120,000$7,532,0001.96%
Valiant Capital Management, L.P. 240,683$15,108,0001.73%
Deuterium Capital Management, LLC 18,000$1,130,0001.45%
View complete list of CRISPR THERAPEUTICS AG shareholders